605 related articles for article (PubMed ID: 7528766)
1. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
[TBL] [Abstract][Full Text] [Related]
2. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF.
Li B; Sallee C; Dehoff M; Foley S; Molina H; Holers VM
J Immunol; 1993 Oct; 151(8):4295-305. PubMed ID: 7691944
[TBL] [Abstract][Full Text] [Related]
3. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
Brodbeck WG; Mold C; Atkinson JP; Medof ME
J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
[TBL] [Abstract][Full Text] [Related]
4. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
5. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation.
Foley S; Li B; Dehoff M; Molina H; Holers VM
Eur J Immunol; 1993 Jun; 23(6):1381-4. PubMed ID: 8500531
[TBL] [Abstract][Full Text] [Related]
6. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
[TBL] [Abstract][Full Text] [Related]
7. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor.
Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC
Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518
[TBL] [Abstract][Full Text] [Related]
8. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.
Kim DD; Miwa T; Song WC
J Immunol; 2006 Oct; 177(8):5558-66. PubMed ID: 17015743
[TBL] [Abstract][Full Text] [Related]
9. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
10. Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46).
Mead R; Hinchliffe SJ; Morgan BP
Immunology; 1999 Sep; 98(1):137-43. PubMed ID: 10469244
[TBL] [Abstract][Full Text] [Related]
11. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3492-502. PubMed ID: 11006244
[TBL] [Abstract][Full Text] [Related]
12. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
13. Functional properties of membrane cofactor protein of complement.
Seya T; Atkinson JP
Biochem J; 1989 Dec; 264(2):581-8. PubMed ID: 2481448
[TBL] [Abstract][Full Text] [Related]
14. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
Matsumoto M; Sugita Y; Seya T
Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
Bjørge L; Jensen TS; Matre R
Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the active sites in decay-accelerating factor.
Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
[TBL] [Abstract][Full Text] [Related]
18. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1.
Molina H; Wong W; Kinoshita T; Brenner C; Foley S; Holers VM
J Exp Med; 1992 Jan; 175(1):121-9. PubMed ID: 1730912
[TBL] [Abstract][Full Text] [Related]
19. Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46.
Iwata K; Seya T; Yanagi Y; Pesando JM; Johnson PM; Okabe M; Ueda S; Ariga H; Nagasawa S
J Biol Chem; 1995 Jun; 270(25):15148-52. PubMed ID: 7541036
[TBL] [Abstract][Full Text] [Related]
20. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
Seya T; Holers VM; Atkinson JP
J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
